Topic Hub
21 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 21 of 21 clinical reviews.
A physician-level review of evolocumab (Repatha) use after bariatric surgery, covering pharmacokinetic changes, dosing, lipid monitoring, and evidence from FOURIER and related trials.
Read clinical reviewA clinician-reviewed, week-by-week guide to what happens during your first month on Repatha (evolocumab): LDL changes, side effects, injection tips, and when to call your doctor.
Read clinical reviewA comprehensive clinical review of evolocumab (Repatha) use in patients with autoimmune conditions, covering PCSK9 biology, trial data, immunogenicity, and prescribing guidance for rheumatologic and inflammatory disease populations.
Read clinical reviewA clinician-level review of evolocumab (Repatha) and its effects on bone mineral density, fracture risk, and PCSK9 biology. Covers FOURIER data, mechanistic pathways, and practical prescribing guidance.
Read clinical reviewA physician-reviewed analysis of the evolocumab (Repatha) cancer risk signal, covering FOURIER trial data, long-term extension studies, mechanistic hypotheses, and current FDA and guideline positions on PCSK9 inhibitor safety.
Read clinical reviewA clinician-level review of evolocumab (Repatha) long-term cardiovascular outcomes, covering FOURIER, FOURIER-OLE, LDL thresholds, dosing, and patient selection for ASCVD and familial hypercholesterolemia.
Read clinical reviewA clinician-level review of evolocumab (Repatha) and cognition, covering FOURIER, EBBINGHAUS, PCSK9 biology, and current ACC/AHA guidance on LDL lowering and brain health.
Read clinical reviewA GRADE-level analysis of evolocumab (Repatha) evidence across FOURIER, GLAGOV, HAUSER-RNT, and ACC/AHA 2022 guidelines. Understand the strength behind the LDL reduction, MACE risk reduction, and safety claims before prescribing.
Read clinical reviewA physician-reviewed guide to evolocumab (Repatha) hair and skin effects, covering FOURIER trial data, PCSK9 biology, real-world reports, and clinical management steps.
Read clinical reviewA physician-level review of evolocumab (Repatha) and liver function: ALT/AST patterns, hepatotoxicity risk, monitoring requirements, and what FOURIER and post-marketing data tell clinicians managing patients on PCSK9 inhibitor therapy.
Read clinical reviewDoes evolocumab (Repatha) affect mood, cognition, or mental health? A physician-reviewed, trial-level analysis of FOURIER, EBBINGHAUS, and post-market safety data for patients and clinicians.
Read clinical reviewDoes evolocumab (Repatha) affect metabolism or energy expenditure? A physician-reviewed deep dive into PCSK9 biology, FOURIER trial data, brown adipose tissue research, and what patients with familial hypercholesterolemia or ASCVD should know.
Read clinical reviewA clinician-level review of evolocumab (Repatha) dosing, PCSK9 inhibitor pharmacology, and why formal microdosing protocols do not yet exist in peer-reviewed guidelines, with a practical decision framework for borderline cases.
Read clinical reviewComprehensive clinical guide on evolocumab (Repatha) muscle preservation strategies, covering FOURIER trial data, statin-associated muscle symptoms, dose optimization, and evidence-based protocols for ASCVD patients.
Read clinical reviewWhy your patient's LDL-C isn't dropping on evolocumab (Repatha), and what to do about it. Covers pseudo-resistance, true non-response, add-on options, and re-challenge protocols with primary-literature citations.
Read clinical reviewA clinician-focused guide to the evolocumab (Repatha) pre-surgery hold window, covering pharmacokinetics, guideline recommendations, FOURIER trial data, and practical perioperative protocols for patients on PCSK9 inhibitor therapy.
Read clinical reviewStopping evolocumab (Repatha) does not cause a rebound LDL spike above pre-treatment baseline. LDL rises back to baseline over 8 to 12 weeks as PCSK9 inhibition wears off. Here is what the clinical data say about discontinuation, and how to manage it.
Read clinical reviewWhen and how to restart Repatha (evolocumab) after acute illness, hospitalization, or surgery. Covers the evidence on LDL rebound, missed-dose pharmacokinetics, and step-by-step re-initiation protocol.
Read clinical reviewA clinician-level guide to evolocumab (Repatha) seasonal use considerations, covering cold-chain storage, injection-site variation, LDL seasonal fluctuation, cardiovascular risk by season, and practical dosing strategies backed by primary literature.
Read clinical reviewA clinician-level review of evolocumab (Repatha) and sexual function, covering FOURIER trial data, cholesterol-testosterone pathways, statin confounding, and what patients and prescribers need to know.
Read clinical reviewDoes evolocumab (Repatha) affect sleep architecture? A deep review of PCSK9 inhibitor neurobiology, CNS cholesterol metabolism, clinical trial sleep data, and practical monitoring guidance for clinicians and patients.
Read clinical review